Zymeworks Acquires Theravance for $929M, but Both Stocks Slide on the Deal
Mondeum Capital (UK) Limited
On Monday, Zymeworks announced it will buy Theravance Biopharma for about $929 million, or $17 per share in cash. Investors in both companies reacted with skepticism. Theravance shares dropped 2.7% to $17.14 in premarket trading, and Zymeworks fell 5.6%. Here’s a look at what each company gains from the deal and why investors are not enthusiastic.
The $17 per share offer is 3.6% lower than Theravance’s closing price of $17.63 last Friday, but it is 22% higher than where the stock traded on March 3, before Theravance announced a late-stage trial failure for its drug ampreloxetine. After that setback, Theravance sped up its search for strategic options and cut its workforce by half. This acquisition brings that process to an end.
Theravance’s only commercial product is Yupelri, a treatment for chronic obstructive pulmonary disease. Yupelri brings in about $60 million a year through U.S. profit sharing and global royalties. Zymeworks says the deal will boost its earnings and cash flow right away, with Yupelri’s revenue being the main reason for the purchase.
Theravance shareholders will also get contingent value rights. These give them 80% of any net proceeds from future licensing, sale, or monetization of ampreloxetine over the next ten years. This means they could still benefit if the failed drug finds a use elsewhere.
The deal should close in the second half of the year. Investors do not seem convinced that Zymeworks is getting a good deal on a troubled asset. The 5.6% drop in Zymeworks’ stock suggests the market sees this as a risky use of capital, not a clear strategic win.
Featured Courses
Recent news
OpenAI Weighs 5% U.S. Government Stake Ahead of Blockbuster IPO
OpenAI has held discussions about offering the U.S. government a 5% ownership stake, potentially structured through a sovereign wealth fund, according to a Financial Times report citing people familiar with the matter. The ChatGPT maker did not immediately respond to a request for comment. The move would add Washington to an already formidable roster of […]
Tesla Deliveries Loom as Investors Bet on Second Straight Quarterly Gain
Tesla is poised to report second-quarter delivery figures Thursday morning, capping a period marked by geopolitical conflict, a spike in oil prices, and continued fallout from shifting U.S. electric-vehicle policy. The automaker’s shares have rallied sharply ahead of the report, a signal that investors anticipate a strong outcome. Even so, forecasts vary widely enough that […]
Nvidia Stock Trails Chip Peers in First Half as Competition Broadens
Nvidia shares rose 0.4% to $195.75 in premarket trading on Tuesday, ending a first half that trailed the broader semiconductor sector. The stock is up 4.5% for the year through Monday, much less than the PHLX Semiconductor Index’s 94% gain over the same period. Here’s a look at why Nvidia has underperformed and what investors […]
Trade with fewer limits
Day trade with fewer limits at fast speed. Buy stocks and ETFs at low fees.